A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 20, 2026

Study Completion Date

December 31, 2028

Conditions

Head and Neck Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab 200mg, IV, 3 cycles

DRUG

Cisplatin

cisplatin 75mg/m2, IV, 3 cycles

DRUG

Nab-paclitaxel

Nab-paclitaxel 260mg, IV, 3 cycles

All Listed Sponsors

lead

Beijing Tongren Hospital

OTHER